Hong Kong stock unusual surging | Kangzhe Pharmaceutical (00867.HK) surged over 4% Its subsidiary, Demai Pharmaceutical, has been approved to conduct clinical trials for the new indication of CMS-D001 innovative drug.

Zhijong Finance and Economics app learned that Kangzhe Pharmaceutical (00867.HK) has risen by more than 4%, as of the time of publication, it has risen by 3.83%, to 13 Hong Kong dollars, with a trading volume of 34.4845 million Hong Kong dollars.